The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-17. Anything still debated is marked as such rather than presented as settled.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
== Antigen processing and presentation == Unlike MHC I, MHC II is meant to present extracellular pathogens rather than intracellular. Furthermore, the first step is to acquire the pathogen through phagocytosis. The pathogen is then broken down in a lysosome and a desired component is then acquired and loaded onto a MHC II molecule. The MHC II molecule then travels to the surface to present the antigen to a helper T cell. MHC II activates helper T cells which help release cytokines and other things which will help induce other cells which help to combat the pathogens outside the cells.
Even more surprising, the researchers determined that the girl's mother's genome was more closely related to Western European Neanderthal DNA, excavated thousands of miles away at the Vindija Cave, Croatia, than the Neanderthals who lived in the Siberian cave where her daughter's remains were found. This finding suggests that Neanderthals migrated in multiple waves from Western Europe to Central Eurasia and encountered the Denisovans several times over a span of tens of thousands of years, and possibly coexisted with them for periods of time.
=== Headache === Doxepin is under development by Winston Pharmaceuticals in an intranasal formulation for the treatment of headache. As of August 2015, it is in phase II clinical trials for this indication.
== Further reading == Dean L (December 2019). "Voriconazole Therapy and CYP2C19 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 31886997.
Sometimes I do not understand them their Inca language, I don't know if they are calm or not!""We no longer have to count on the Chileans and Argentines, and these Peruvians are the most miserable men for war. Of course, we must resolve to sustain this fight alone." Hiram Paulding, a US sailor who visited him in his camp in Huaraz, recounts that Bolívar told him that the Peruvians "were cowards and that, as a people, they did not have a single manly virtue. In short, his insults were harsh and unreserved... Then they told me that he always used to speak like that about Peruvians." According to Jorge Basadre, Bolívar's anti-Peruvian feelings would explain his triumphalist proclamations with Colombia, where he declared, after the Battle of Ayacucho, that "The loyalty, perseverance and courage of the Colombian army has done everything". Given this, it has been denounced that Bolívar had a very unpleasant treatment with the Peruvian troops under his command, an example is in a case that occurred with Ramon Castilla, who for trying to prevent a Peruvian cavalry corps from being arbitrarily added to a Gran Colombian unit during the Junín campaign, the young Peruvian soldier would suffer a humiliating insult: the Venezuelans (under the command of Bolívar) would have him put in stocks, and even wanted to shoot him, despite being part of the same side and in combat against the royalists. In the process a duel took place between the Cuiraceros of Peru and the Hussars of Colombia that took place on December 26, 1823.
Sources: en.wikipedia.org
In 2010, over 136 students graduated with degree or diploma. In 2013, 347 students graduated with degree or diploma, of whom 31% were female. In 2014, 477 students graduated with degree or diploma, of whom 34% were female. In 2015, 416 students graduated with degree or diploma, of whom 40% were female. In 2016, 367 students graduated with degree or diploma, of whom 40% were female. in 2018, 459 students graduated with degree or diploma. In 2013, the number of the students was reported as increasing by more than 10% each year.
This reaction is exploited in native chemical ligation, a protocol for peptide synthesis. In a related reaction, thioesters can be converted into esters. Thioacetate esters can also be cleaved with methanethiol in the presence of stoichiometric base, as illustrated in the preparation of pent-4-yne-1-thiol:
=== Antipsychotics === Olanzapine and risperidone are atypical antipsychotics which are also effective in GAD and PTSD treatment. However, there is a higher chance of experiencing adverse effects than the other anti-anxiety medications.
== History == Lurbinectedin was approved for medical use in the United States in June 2020. Efficacy was demonstrated in the PM1183-B-005-14 trial (Study B-005; NCT02454972), a multi-center open-label, multi-cohort study enrolling 105 participants with metastatic small cell lung cancer who had disease progression on or after platinum-based chemotherapy. Participants received lurbinectedin 3.2 mg/m2 by intravenous infusion every 21 days until disease progression or unacceptable toxicity. The trial was conducted at 26 sites in the United States, Great Britain, Belgium, France, Italy, Spain and Czech Republic. The US Food and Drug Administration (FDA) granted the application for lurbinectedin priority review and orphan drug designations and granted the approval of Zepzelca to Pharma Mar S.A. The efficacy of lurbinectedin used in combination with atezolizumab or in combination with atezolizumab/hyaluronidase was evaluated in IMforte (NCT05091567), a randomized, multi-center, open-label trial in participants receiving first-line treatment for extensive-stage small cell lung cancer. In IMforte, 483 participants with extensive-stage small cell lung cancer whose disease had not progressed after completion of four cycles of atezolizumab, carboplatin, and etoposide (induction treatment) were randomized (1:1) to receive either lurbinectedin in combination with atezolizumab administered intravenously or atezolizumab intravenously alone until disease progression or unacceptable toxicity.
Sources: en.wikipedia.org
== Technical characteristics == Modern systems (for smaller, i.e. “normal”, tube diameters as used in the transport of small capsules) reach speeds of around 7.5 m (25 ft) per second, though some historical systems already achieved speeds of 10 m (33 ft) per second. At the same time, varying air pressures allow capsules to brake slowly, removing the jarring arrival that used to characterise earlier systems and make them unsuitable for fragile contents. Very powerful systems can transport items with a weight of up to 50 kg (110 lb) and a diameter of up to 500 mm (20 in). More than 100 lines and 1000 stations can be connected. Further, modern systems can be computer-controlled for tracking of any specific capsule and managing priority deliveries as well as system efficiency. With this technology, time-critical items can be transported, such as tissue samples taken during a surgery in a hospital. RFID chips within the capsules gather data – e. g. about the location of the carrier, its transport speed or its destination. The systems collect and save these data to help users optimize their internal processes and turnaround times. The facilities can be linked to the company's software systems, e.g. laboratory information systems, for full integration into company logistical management and production chains.
== Further reading == ABC News gallery of Cheese seized by the Dallas ISD Pantazi, Andrew. "‘Cheese’ heroin led Dallas 13-year-old to a life on the edge." The Dallas Morning News. 29 December 2012. Updated 30 December 2012. Dave Montgomery. "Law enforcement worries 'cheese heroin' could spread," McClatchy Newspapers, July 18, 2007. Maxwell, Jane C., PhD (Senior Research Scientist, University of Texas at Austin Gulf Coast Addiction Technology Transfer Center). "“Cheese” Heroin: Status as of May 2, 2007" (Archive) Merlan, Anna. "In Suburban Dallas, Loosening "Cheese" Heroin's Deadly Grip Archived 2013-10-13 at the Wayback Machine." Dallas Observer. July 28, 2011. Merlan, Anna. "Why Does Dallas Keep Forgetting About its Cheese-Heroin Problem? Archived 2012-12-24 at the Wayback Machine" Dallas Observer. May 21, 2012. "Dallas Man Sentenced to a Total of 240 Months in Federal Prison for Role in Heroin Distribution Conspiracies." (Archive[link removed]) United States Department of Justice. November 5, 2013. Tracy Sabo. "Deadly $2 heroin targets teens," CNN, June 12, 2007. "New Drug Hits the Street? A 'Poor Man's Heroin' For Kids", Pine Magazine, June 12, 2007.
=== Other appearances === "TV Eye" with Wylde Ratttz, Velvet Goldmine: Music from the Original Motion Picture, 1999. "Elephant Love Medley" with Nicole Kidman, Moulin Rouge! Music from Baz Luhrmann's Film, 2001. "El Tango de Roxanne" with Jose Feliciano, Moulin Rouge! Music from Baz Luhrmann's Film, 2001. "Your Song" with Alessandro Safina, Moulin Rouge! Music from Baz Luhrmann's Film, 2001. "Here's To Love" with Renée Zellweger, Down With Love: Music from and Included in the Motion Picture, 2003. "The Sweetest Gift", Unexpected Dreams – Songs From the Stars, 2006. "Be Our Guest" with Emma Thompson, Ian McKellen, and Gugu Mbatha-Raw, Beauty and the Beast, 2017. "Days in the Sun" with Adam Mitchell, Stanley Tucci, Ian McKellen, Emma Thompson, Emma Watson, Audra McDonald, Clive Rowe, Beauty and the Beast, 2017. "Something There" with Emma Watson, Dan Stevens, Ian McKellen, Emma Thompson, Nathan Mack, Gugu Mbatha-Raw, Beauty and the Beast, 2017. "The Mob Song", with Luke Evans, Josh Gad, Emma Thompson, Ian McKellen, Stanley Tucci, Nathan Mack, & Gugu Mbatha-Raw, Beauty and the Beast, 2017. "Better Tomorrows", Pinocchio, 2022.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.